Schlusswort

In Reply

Dtsch Arztebl Int 2012; 109(17): 313-4; DOI: 10.3238/arztebl.2012.0313b

1.	Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC). J Hypertens 2007; 25: 1105–87. CrossRef MEDLINE
2.	Vaclavik J, Sedlak R, Plachy M, et al.: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069–7. CrossRef MEDLINE
3.	The Symplicity HTN-1 Investigators: Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911–7. CrossRef MEDLINE
4.	Esler MD, Krum H, Sobotka PA, et al.: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903–9. CrossRef MEDLINE
5.	Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J: Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011; 108(43): 725–31. VOLLTEXT

Eingeloggt als $LOGINEMAIL$